Zoetis Inc. (NYSE:ZTS) Shares Acquired by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 20,604 shares of the company’s stock after acquiring an additional 153 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Zoetis were worth $4,067,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Bell Private Wealth Management LLC increased its position in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Independence Bank of Kentucky increased its position in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares during the period. Ramirez Asset Management Inc. acquired a new position in Zoetis during the third quarter worth approximately $35,000. First Financial Corp IN increased its position in Zoetis by 57.2% during the fourth quarter. First Financial Corp IN now owns 217 shares of the company’s stock worth $43,000 after buying an additional 79 shares during the period. Finally, FinTrust Capital Advisors LLC increased its position in Zoetis by 42.1% during the third quarter. FinTrust Capital Advisors LLC now owns 260 shares of the company’s stock worth $45,000 after buying an additional 77 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now directly owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $371,293 over the last three months. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

ZTS has been the topic of several analyst reports. Barclays lowered their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group lifted their price target on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus decreased their price target on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Piper Sandler restated an “overweight” rating and issued a $195.00 price target (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $216.13.

Zoetis Price Performance

ZTS traded down $0.16 during trading on Friday, reaching $167.07. 3,007,125 shares of the stock were exchanged, compared to its average volume of 4,607,073. The business’s 50 day moving average price is $168.88 and its two-hundred day moving average price is $178.84. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The company has a market capitalization of $76.41 billion, a price-to-earnings ratio of 32.19, a P/E/G ratio of 2.62 and a beta of 0.86. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The company had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. Zoetis’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.31 earnings per share. As a group, equities research analysts anticipate that Zoetis Inc. will post 5.78 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.